Wall Street expects earnings per share (EPS) of $2.26, with analysts projecting a slightly higher EPS of$2.28.Revenue forecast is approximately $13.87 billion, closely followed by analysts' estimates of$13.7 billion.Novartis showcases a price-to-earnings (P/E) ratio of 18.99 and a beta of 0.64, indicating moderate volatility.Novartis AG, listed on the NYSE:NVS, is a global healthcare company known for its innovative medicines and treatments. The company is a major player in the pharmaceutical industry, co ...